Insight Molecular Diagnostics Inc. (IMDX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.90

From 52W high−52.83%

Volume317921.00

Market cap$130.90M

P/E (TTM)—

P/S (TTM)78.4x

Div yield—

Key dataSep 18, 2026

Open

$3.90

From 52W high

−52.83%

Volume

317921.00

Market cap

$130.90M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.5x

P/E (TTM)

—

RSI (14)

43.5

MomentumView details →

1D Return

+1.27%

YTD Return

−48.13%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.5x

EV/Sales

69.3x

P/S (TTM)

78.4x

P/B (TTM)

−6.1x

ProfitabilityView details →

Gross Margin

11.17%

Net Margin

−2955.63%

EBITDA Margin

−2803.47%

ROE (TTM)

231.74%

ROA (TTM)

−167.64%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

−60.77%

EPS YoY

+56.27%

FCF YoY

−30.29%

Revenue CAGR 3Y

+61.76%

EPS CAGR 3Y

+64.60%

EBITDA YoY

+23.69%

MomentumView details →

1D Return

+1.27%

YTD Return

−48.13%

1Y Return

+14.08%

RSI (14)

43.5

vs 50D SMA

−12.17%

vs 200D SMA

−24.49%

Capital & dividendView details →

Debt/Equity

−0.12x

Current Ratio

2.00x

Quick Ratio

1.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.31

EPS Surprise

−22.07%

Beats (12Q)

7/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

42.20%

Rev Surprise

−45.37%

Financials snapshotView financials →

Revenue (TTM)

1.67M

Net Income (TTM)

−49.36M

Op. CF (TTM)

−26.95M

Next earningsNov 9, 2026 →

Latest newsMore news →

Insight Molecular Diagnostics Inc. highlighted a favorable new Medicare policy that expands coverage for donor-derived cell-free DNA testing in transplant care.66d ago

Similar companies

Biomea Fusion, Inc.BMEA Inovio Pharmaceuticals, Inc.INO Unicycive Therapeutics, Inc.UNCY TuHURA Biosciences, Inc.HURA enGene Holdings Inc.ENGN LENZ Therapeutics, Inc.LENZ Find similar companies →

Latest newsMore news →

Insight Molecular Diagnostics Inc. highlighted a favorable new Medicare policy that expands coverage for donor-derived cell-free DNA testing in transplant care.66d ago